Patents by Inventor Laure Bachelet

Laure Bachelet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fucoidans as ligands for the diagnosis of degenerative pathologies
    Patent number: 11154625
    Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: October 26, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS 13
    Inventors: Jean-Baptiste Michel, Didier Letourneur, Frederic Chaubet, Laure Bachelet, Francois Rouzet, Alain Meulemans
  • Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies
    Publication number: 20140134102
    Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Jean-Baptiste Michel, Didier Letourneur, Frederic Chaubet, Laure Bachelet, Francois Rouzet, Alain Meulemans
  • Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies
    Publication number: 20120183475
    Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.
    Type: Application
    Filed: January 9, 2012
    Publication date: July 19, 2012
    Applicant: INSERM (Institut National de la sante et de la Recherche Medicale)
    Inventors: Jean-Baptiste Michel, Didier Letourneur, Frederic Chaubet, Laure Bachelet, Francois Rouzet, Alain Meulemans
  • Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies
    Publication number: 20120093725
    Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.
    Type: Application
    Filed: April 10, 2009
    Publication date: April 19, 2012
    Applicant: Inserm (Institut National de la Sante et de la Recherche Medicale
    Inventors: Jean-Baptiste Michel, Didier Letourneur, Frederic Chaubet, Laure Bachelet, Francois Rouzet, Alain Meulemans